262 related articles for article (PubMed ID: 12359676)
1. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine.
Gilmor ML; Owens MJ; Nemeroff CB
Am J Psychiatry; 2002 Oct; 159(10):1702-10. PubMed ID: 12359676
[TBL] [Abstract][Full Text] [Related]
2. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.
Béïque JC; Lavoie N; de Montigny C; Debonnel G
Eur J Pharmacol; 1998 May; 349(1):129-32. PubMed ID: 9669506
[TBL] [Abstract][Full Text] [Related]
3. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine.
Owens MJ; Krulewicz S; Simon JS; Sheehan DV; Thase ME; Carpenter DJ; Plott SJ; Nemeroff CB
Neuropsychopharmacology; 2008 Dec; 33(13):3201-12. PubMed ID: 18418363
[TBL] [Abstract][Full Text] [Related]
4. Fluoxetine and desipramine selectively attenuate 2'-NH2-MPTP-induced depletions in serotonin and norepinephrine.
Andrews AM; Murphy DL
Eur J Pharmacol; 1993 Dec; 250(2):215-21. PubMed ID: 8112382
[TBL] [Abstract][Full Text] [Related]
5. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats.
Davids E; Zhang K; Kula NS; Tarazi FI; Baldessarini RJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1097-102. PubMed ID: 12023542
[TBL] [Abstract][Full Text] [Related]
6. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.
Pollock BG; Ferrell RE; Mulsant BH; Mazumdar S; Miller M; Sweet RA; Davis S; Kirshner MA; Houck PR; Stack JA; Reynolds CF; Kupfer DJ
Neuropsychopharmacology; 2000 Nov; 23(5):587-90. PubMed ID: 11027924
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies.
Bel N; Artigas F
J Pharmacol Exp Ther; 1996 Sep; 278(3):1064-72. PubMed ID: 8819487
[TBL] [Abstract][Full Text] [Related]
8. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.
Yoshida K; Takahashi H; Higuchi H; Kamata M; Ito K; Sato K; Naito S; Shimizu T; Itoh K; Inoue K; Suzuki T; Nemeroff CB
Am J Psychiatry; 2004 Sep; 161(9):1575-80. PubMed ID: 15337646
[TBL] [Abstract][Full Text] [Related]
9. Conclusive evidence for distinct transporters for 5-hydroxytryptamine and noradrenaline in pulmonary endothelial cells of the rat.
Paczkowski NJ; Vuocolo HE; Bryan-Lluka LJ
Naunyn Schmiedebergs Arch Pharmacol; 1996 Mar; 353(4):423-30. PubMed ID: 8935709
[TBL] [Abstract][Full Text] [Related]
10. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.
Aldosary F; Norris S; Tremblay P; James JS; Ritchie JC; Blier P
Int J Neuropsychopharmacol; 2022 Apr; 25(4):283-292. PubMed ID: 34958348
[TBL] [Abstract][Full Text] [Related]
11. Neuropharmacology of paroxetine.
Nemeroff CB; Owens MJ
Psychopharmacol Bull; 2003; 37 Suppl 1():8-18. PubMed ID: 14566196
[TBL] [Abstract][Full Text] [Related]
12. Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin.
Narayan M; Anderson G; Cellar J; Mallison RT; Price LH; Nelson JC
J Clin Psychopharmacol; 1998 Feb; 18(1):67-71. PubMed ID: 9472845
[TBL] [Abstract][Full Text] [Related]
13. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study.
Nelson JC; Mazure CM; Jatlow PI; Bowers MB; Price LH
Biol Psychiatry; 2004 Feb; 55(3):296-300. PubMed ID: 14744472
[TBL] [Abstract][Full Text] [Related]
14. Efflux studies allow further characterisation of the noradrenaline and 5-hydroxytryptamine transporters in rat lungs.
James KM; Bryan-Lluka LJ
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jul; 356(1):126-33. PubMed ID: 9228199
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB
J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
[TBL] [Abstract][Full Text] [Related]
16. Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transporter inhibitors.
Zhang A; Zhou G; Hoepping A; Mukhopadhyaya J; Johnson KM; Zhang M; Kozikowski AP
J Med Chem; 2002 Apr; 45(9):1930-41. PubMed ID: 11960503
[TBL] [Abstract][Full Text] [Related]
17. Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice.
Montañez S; Owens WA; Gould GG; Murphy DL; Daws LC
J Neurochem; 2003 Jul; 86(1):210-9. PubMed ID: 12807440
[TBL] [Abstract][Full Text] [Related]
18. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d'Expérimentation Psychopharmacologique.
Bordet R; Thomas P; Dupuis B
Am J Psychiatry; 1998 Oct; 155(10):1346-51. PubMed ID: 9766765
[TBL] [Abstract][Full Text] [Related]
19. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat.
Béïque J; de Montigny C; Blier P; Debonnel G
Neuropharmacology; 2000 Jul; 39(10):1813-22. PubMed ID: 10884562
[TBL] [Abstract][Full Text] [Related]
20. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
